FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2955874948> ?p ?o ?g. }

• W2955874948 endingPage "856" @default.
• W2955874948 startingPage "845" @default.
• W2955874948 abstract "Background Opicinumab is a human monoclonal antibody against LINGO-1, an inhibitor of oligodendrocyte differentiation and axonal regeneration. Previous findings suggested that opicinumab treatment might enhance remyelination in patients with CNS demyelinating diseases. We aimed to assess the safety and efficacy of opicinumab in patients with relapsing multiple sclerosis. Methods We did a randomised, double-blind, placebo-controlled, dose-ranging, phase 2 study (SYNERGY) at 72 sites in 12 countries. Participants (aged 18–58 years) with relapsing multiple sclerosis (relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis with relapses) were randomised in a 1:2:2:2:2 ratio by an interactive voice and web response system to opicinumab 3 mg/kg, 10 mg/kg, 30 mg/kg, or 100 mg/kg, or placebo. An identical volume of study drug was administered intravenously once every 4 weeks. All participants self-administered intramuscular interferon beta-1a as background anti-inflammatory treatment once a week. The primary endpoint was the percentage of participants achieving confirmed disability improvement over 72 weeks, which was a multicomponent endpoint measured by the Expanded Disability Status Scale, the Timed 25-Foot Walk, the Nine-Hole Peg Test, and the 3 s Paced Auditory Serial Addition Test. The primary endpoint was analysed under intention-to-treat principles. This study is registered at ClinicalTrials.gov, number NCT01864148. Findings Between Aug 13, 2013, and July 31, 2014, 419 patients were enrolled and randomly assigned either placebo (n=93) or opicinumab 3 mg/kg (n=45), 10 mg/kg (n=95), 30 mg/kg (n=94; one patient did not receive the assigned treatment), or 100 mg/kg (n=92). The last patient visit was on March 29, 2016. Confirmed disability improvement over 72 weeks was seen in 45 (49%) of 91 patients assigned to placebo, 21 (47%) of 45 assigned to opicinumab 3 mg/kg, 59 (63%) of 94 assigned to opicinumab 10 mg/kg, 59 (65%) of 91 assigned to opicinumab 30 mg/kg, and 36 (40%) of 91 assigned to opicinumab 100 mg/kg. A linear dose-response in the probability of confirmed disability improvement was not seen (linear trend test p=0·89). Adverse events occurred in 79 (85%) patients assigned placebo and in 275 (85%) assigned any dose of opicinumab. The most common adverse events of any grade in patients assigned any dose of opicinumab included influenza-like illness (140 [43%] with any dose of opicinumab vs 37 [40%] with placebo), multiple sclerosis relapses (117 [36%] vs 30 [32%]), and headache (51 [16%] vs 23 [25%]). Serious adverse events reported as related to treatment were urinary tract infection in one (1%) participant in the the placebo group, suicidal ideation and intentional overdose in one (1%) participant in the 30 mg/kg opicinumab group, bipolar disorder in one (1%) participant in the 100 mg/kg opicinumab group, and hypersensitivity in four (4%) participants in the 100 mg/kg opicinumab group. One patient in the opicinumab 30 mg/kg group died during the study due to a traffic accident, which was not considered related to study treatment. Interpretation Our findings did not show a significant dose-linear improvement in disability compared with placebo in patients with relapsing multiple sclerosis. Further studies are needed to investigate whether some subpopulations identified in the study might benefit from opicinumab treatment at an optimum dose. Funding Biogen. Opicinumab is a human monoclonal antibody against LINGO-1, an inhibitor of oligodendrocyte differentiation and axonal regeneration. Previous findings suggested that opicinumab treatment might enhance remyelination in patients with CNS demyelinating diseases. We aimed to assess the safety and efficacy of opicinumab in patients with relapsing multiple sclerosis. We did a randomised, double-blind, placebo-controlled, dose-ranging, phase 2 study (SYNERGY) at 72 sites in 12 countries. Participants (aged 18–58 years) with relapsing multiple sclerosis (relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis with relapses) were randomised in a 1:2:2:2:2 ratio by an interactive voice and web response system to opicinumab 3 mg/kg, 10 mg/kg, 30 mg/kg, or 100 mg/kg, or placebo. An identical volume of study drug was administered intravenously once every 4 weeks. All participants self-administered intramuscular interferon beta-1a as background anti-inflammatory treatment once a week. The primary endpoint was the percentage of participants achieving confirmed disability improvement over 72 weeks, which was a multicomponent endpoint measured by the Expanded Disability Status Scale, the Timed 25-Foot Walk, the Nine-Hole Peg Test, and the 3 s Paced Auditory Serial Addition Test. The primary endpoint was analysed under intention-to-treat principles. This study is registered at ClinicalTrials.gov, number NCT01864148. Between Aug 13, 2013, and July 31, 2014, 419 patients were enrolled and randomly assigned either placebo (n=93) or opicinumab 3 mg/kg (n=45), 10 mg/kg (n=95), 30 mg/kg (n=94; one patient did not receive the assigned treatment), or 100 mg/kg (n=92). The last patient visit was on March 29, 2016. Confirmed disability improvement over 72 weeks was seen in 45 (49%) of 91 patients assigned to placebo, 21 (47%) of 45 assigned to opicinumab 3 mg/kg, 59 (63%) of 94 assigned to opicinumab 10 mg/kg, 59 (65%) of 91 assigned to opicinumab 30 mg/kg, and 36 (40%) of 91 assigned to opicinumab 100 mg/kg. A linear dose-response in the probability of confirmed disability improvement was not seen (linear trend test p=0·89). Adverse events occurred in 79 (85%) patients assigned placebo and in 275 (85%) assigned any dose of opicinumab. The most common adverse events of any grade in patients assigned any dose of opicinumab included influenza-like illness (140 [43%] with any dose of opicinumab vs 37 [40%] with placebo), multiple sclerosis relapses (117 [36%] vs 30 [32%]), and headache (51 [16%] vs 23 [25%]). Serious adverse events reported as related to treatment were urinary tract infection in one (1%) participant in the the placebo group, suicidal ideation and intentional overdose in one (1%) participant in the 30 mg/kg opicinumab group, bipolar disorder in one (1%) participant in the 100 mg/kg opicinumab group, and hypersensitivity in four (4%) participants in the 100 mg/kg opicinumab group. One patient in the opicinumab 30 mg/kg group died during the study due to a traffic accident, which was not considered related to study treatment. Our findings did not show a significant dose-linear improvement in disability compared with placebo in patients with relapsing multiple sclerosis. Further studies are needed to investigate whether some subpopulations identified in the study might benefit from opicinumab treatment at an optimum dose." @default.
• W2955874948 created "2019-07-12" @default.
• W2955874948 creator A5001299036 @default.
• W2955874948 creator A5001899447 @default.
• W2955874948 creator A5002317679 @default.
• W2955874948 creator A5002722246 @default.
• W2955874948 creator A5003803499 @default.
• W2955874948 creator A5006513938 @default.
• W2955874948 creator A5006639733 @default.
• W2955874948 creator A5006830562 @default.
• W2955874948 creator A5007277741 @default.
• W2955874948 creator A5007615278 @default.
• W2955874948 creator A5007722789 @default.
• W2955874948 creator A5007805719 @default.
• W2955874948 creator A5008598861 @default.
• W2955874948 creator A5010335156 @default.
• W2955874948 creator A5011705068 @default.
• W2955874948 creator A5011707167 @default.
• W2955874948 creator A5013424043 @default.
• W2955874948 creator A5014513997 @default.
• W2955874948 creator A5015754502 @default.
• W2955874948 creator A5016600721 @default.
• W2955874948 creator A5019520718 @default.
• W2955874948 creator A5020016996 @default.
• W2955874948 creator A5020842633 @default.
• W2955874948 creator A5021092653 @default.
• W2955874948 creator A5021292901 @default.
• W2955874948 creator A5022419928 @default.
• W2955874948 creator A5024154909 @default.
• W2955874948 creator A5024478639 @default.
• W2955874948 creator A5025115336 @default.
• W2955874948 creator A5026572220 @default.
• W2955874948 creator A5028376814 @default.
• W2955874948 creator A5031140141 @default.
• W2955874948 creator A5031171090 @default.
• W2955874948 creator A5031308593 @default.
• W2955874948 creator A5031564335 @default.
• W2955874948 creator A5033218374 @default.
• W2955874948 creator A5035093314 @default.
• W2955874948 creator A5035645353 @default.
• W2955874948 creator A5036234809 @default.
• W2955874948 creator A5036441867 @default.
• W2955874948 creator A5038394370 @default.
• W2955874948 creator A5038662347 @default.
• W2955874948 creator A5044245930 @default.
• W2955874948 creator A5045188612 @default.
• W2955874948 creator A5045210357 @default.
• W2955874948 creator A5046335295 @default.
• W2955874948 creator A5047268222 @default.
• W2955874948 creator A5048547477 @default.
• W2955874948 creator A5050715580 @default.
• W2955874948 creator A5051546835 @default.
• W2955874948 creator A5053042833 @default.
• W2955874948 creator A5053461332 @default.
• W2955874948 creator A5053867003 @default.
• W2955874948 creator A5055427861 @default.
• W2955874948 creator A5057269185 @default.
• W2955874948 creator A5059125322 @default.
• W2955874948 creator A5059693967 @default.
• W2955874948 creator A5061043692 @default.
• W2955874948 creator A5061735741 @default.
• W2955874948 creator A5061851273 @default.
• W2955874948 creator A5062241641 @default.
• W2955874948 creator A5062458064 @default.
• W2955874948 creator A5062651960 @default.
• W2955874948 creator A5063615479 @default.
• W2955874948 creator A5063711884 @default.
• W2955874948 creator A5063721700 @default.
• W2955874948 creator A5064338988 @default.
• W2955874948 creator A5065413693 @default.
• W2955874948 creator A5066151139 @default.
• W2955874948 creator A5066280314 @default.
• W2955874948 creator A5066298482 @default.
• W2955874948 creator A5068759242 @default.
• W2955874948 creator A5069196741 @default.
• W2955874948 creator A5069704075 @default.
• W2955874948 creator A5071409158 @default.
• W2955874948 creator A5071667577 @default.
• W2955874948 creator A5071938770 @default.
• W2955874948 creator A5072872904 @default.
• W2955874948 creator A5073757836 @default.
• W2955874948 creator A5074035716 @default.
• W2955874948 creator A5076958249 @default.
• W2955874948 creator A5077701566 @default.
• W2955874948 creator A5079905053 @default.
• W2955874948 creator A5080108966 @default.
• W2955874948 creator A5080257392 @default.
• W2955874948 creator A5081187567 @default.
• W2955874948 creator A5081289018 @default.
• W2955874948 creator A5081607909 @default.
• W2955874948 creator A5082895881 @default.
• W2955874948 creator A5084501846 @default.
• W2955874948 creator A5084526963 @default.
• W2955874948 creator A5085187558 @default.
• W2955874948 creator A5085871283 @default.
• W2955874948 creator A5086303243 @default.
• W2955874948 creator A5087362850 @default.
• W2955874948 creator A5088163706 @default.

• next